Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMRYH3M)

Drug Name
ADP-A2M4 Drug Info
Indication
Disease Entry ICD 11 Status REF
Synovial sarcoma 2B5A Phase 2 [1]
Solid tumour/cancer 2A00-2F9Z Phase 1 [2]
Cross-matching ID
TTD Drug ID
DMRYH3M

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Melanoma-associated antigen 4 (MAGEA4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Afamitresgene autoleucel DM1GR4M Soft tissue sarcoma 2B57 Phase 2 [3]
CAR-T cells targeting MAGE-A4 DMUBEX4 Lung cancer 2C25.0 Phase 1/2 [4]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Melanoma-associated antigen 4 (MAGEA4) TT9EQUY MAGA4_HUMAN Not Available [1]

References

1 Clinical pipeline report, company report or official report of Adaptimmune.
2 Clinical pipeline report, company report or official report of Adaptimmune.
3 Autologous T cell therapy for MAGE-A4(+) solid cancers in HLA-A*02(+) patients: a phase 1 trial. Nat Med. 2023 Jan;29(1):104-114.
4 ClinicalTrials.gov (NCT03356808) Antigen-specific T Cells Against Lung Cancer